WallStreetZenWallStreetZen

NASDAQ: FATE
Fate Therapeutics Inc Stock Ownership - Who owns Fate Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Fate Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Edward J. Dulac IiiChief Financial Officer2024-03-042,447$7.77
$19.01kSell
Edward J. Dulac IiiChief Financial Officer2024-01-291,849$5.00
$9.25kSell
Cindy TahlGeneral Counsel and Secretary2024-01-0910,874$4.37
$47.52kSell
Edward J. Dulac IiiChief Financial Officer2024-01-097,028$4.37
$30.71kSell
J. Scott WolchkoPresident and CEO2024-01-0914,391$4.37
$62.89kSell
Bahram ValamehrChief RD Officer2024-01-0911,271$4.38
$49.37kSell
Edward J. Dulac IiiChief Financial Officer2024-01-025,182$3.66
$18.97kSell
Redmile Group LLCDirector2023-12-2644,630$3.72
$166.02kBuy
Redmile Group LLCDirector2023-12-261,655,370$3.72
$6.16MBuy
Redmile Group LLCDirector2023-12-261,655,370$3.72
$6.16MSell

1 of 2

FATE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FATE insiders and whales buy or sell their stock.

FATE Shareholders

What type of owners hold Fate Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Redmile Group LLC26.35%26,148,941$105.64MInsider
Redmile Group LLC13.27%13,169,057$53.20MInstitution
Blackrock Inc11.30%11,212,816$45.30MInstitution
Amir Nashat9.93%9,852,967$39.81MInsider
Polaris Venture Management Co V LLC9.92%9,841,933$39.76MInsider
Vanguard Group Inc9.36%9,293,363$37.55MInstitution
Bellevue Group Ag4.89%4,851,579$19.60MInstitution
D E Shaw Co Inc3.61%3,581,979$14.47MInstitution
Point72 Asset Management LP3.52%3,489,163$14.10MInstitution
Johnson Johnson3.41%3,379,064$13.65MInstitution

1 of 3

FATE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FATE61.86%38.14%Net SellingNet Selling
MNMD10.01%89.99%Net SellingNet Selling
REPL67.71%32.29%Net Selling
CRBP5.76%94.24%Net BuyingNet Buying
PEPG50.08%18.34%Net BuyingNet Buying
View Top Biotech Stocks

Fate Therapeutics Stock Ownership FAQ

Who owns Fate Therapeutics?

Fate Therapeutics (NASDAQ: FATE) is owned by 96.01% institutional shareholders, 59.19% Fate Therapeutics insiders, and 0.00% retail investors. Redmile Group LLC is the largest individual Fate Therapeutics shareholder, owning 26.15M shares representing 26.35% of the company. Redmile Group LLC's Fate Therapeutics shares are currently valued at $103.29M.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.